TRIPLE NEGATIVE BREAST CANCER

This early-phase trial tests a personalized vaccine made from a patient's own immune cells (dendritic cells) trained to recognize unique proteins from their leftover breast tumor after standard chemotherapy and surgery. The goal is to see if the vaccine is safe and can boost the …

This study tests a new vaccine called Modi-1, designed to train the immune system to attack cancer cells. It is given as a tiny shot into the skin using a special microneedle device. The trial includes 168 people with advanced triple-negative breast cancer, head and neck cancer, …

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-stage trial is testing a new type of immune cell therapy called CAR-T cells that target a protein called B7-H3 on triple-negative breast cancer cells. The cells also have a safety switch to stop them if needed. Up to 42 adults whose cancer has returned or not responded…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…

This Phase 3 trial is testing whether a new drug called datopotamab deruxtecan (Dato-DXd), given alone or with another drug called durvalumab, works better than standard chemotherapy for people with a certain type of advanced triple-negative breast cancer (PD-L1 positive). About …

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This study tests whether a combination of two drugs (sacituzumab govitecan and pembrolizumab) given after surgery works better than standard treatments to prevent breast cancer from coming back. It is for people with triple negative breast cancer who still have cancer cells in th…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This early-stage trial is testing a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to see if the drug is safe and to find the best dose. Researchers will also watch for any signs t…

This phase II trial is testing a drug called ARX788 in 36 people with HER2-low breast cancer that has spread or cannot be removed. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The main goal is to see how many patients'…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This early-stage trial tests a new drug called MST-0312, designed to help the body's immune system fight cancer more effectively. It is being studied alone or with another cancer drug (pembrolizumab) in people with several types of solid tumors, including lung, melanoma, bladder,…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This phase 2 study is testing a drug called sacituzumab govitecan, alone or with pembrolizumab, given before surgery to people with localized triple-negative breast cancer. The goal is to see if these drugs can eliminate all cancer cells in the breast and lymph nodes before surge…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This early-phase trial is testing a personalized oral DNA vaccine called NECVAX-NEO1 in 28 people with triple-negative breast cancer. The vaccine is given alongside standard chemotherapy and an immunotherapy drug before and after surgery. The goal is to see if it is safe and help…

This study is for women with a type of advanced breast cancer called triple-negative breast cancer that does not have the PDL1 protein. It tests whether adding an immunotherapy drug (durvalumab) to a targeted chemotherapy (datopotamab deruxtecan) works better than the chemotherap…

This early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune response to the drug pembrolizumab in people with metastatic or locally advanced triple negative breast cancer. About 30 participants will be randomly assigned to receive either the combinat…

This phase 2 trial is testing whether adding a targeted drug called patritumab deruxtecan to standard immunotherapy and chemotherapy can improve outcomes for people with high-risk early-stage triple-negative or hormone receptor-low positive breast cancer. About 372 participants w…

This early-phase trial tests a new cell therapy for people with advanced triple negative breast cancer that has stopped responding to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a …

This early-phase trial tests AVA6000, a chemotherapy drug that is designed to activate only in tumors, potentially reducing side effects. About 158 adults with advanced solid tumors (like breast, ovarian, or salivary gland cancer) will receive the drug intravenously. The main goa…

This phase 2 trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. The study will enroll 46 participants and measure how many achieve a complete response (no c…

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …

This study tests whether a high-fiber diet (20-30 grams per day) combined with mind-body support can help women with triple-negative breast cancer undergoing immunotherapy and chemotherapy. Sixty participants will either receive online group training or a simple nutrition flyer. …

This study tests whether adding tocilizumab, an anti-inflammatory drug, to standard chemotherapy improves outcomes for people with metastatic triple-negative or ER-low breast cancer. Researchers will compare the combination to chemotherapy alone in 168 Black and non-Black patient…

This phase 3 trial tests whether the drug SKB264 works better than standard chemotherapy as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. About 524 participants will be randomly assigned to receive eith…

This early-stage study is testing a new oral drug, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Abo…

This study tests a 12-18 week treatment without anthracyclines (a type of chemo that can harm the heart) for people with triple-negative breast cancer who already have heart conditions or are at high risk for heart damage. The treatment combines two chemotherapy drugs (carboplati…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study tests whether combining two drugs, sacituzumab govitecan and atezolizumab, can clear leftover cancer cells in the breast or lymph nodes of people with triple negative breast cancer. About 40 participants who still have cancer after standard chemotherapy will receive th…

This study tests whether adding pembrolizumab to sacituzumab govitecan helps control metastatic triple-negative breast cancer that is PD-L1-negative. About 110 adults with advanced TNBC will be randomly assigned to receive either the combination or sacituzumab alone. The goal is …

This early-stage trial is testing a new type of targeted radiation therapy for people with advanced pancreatic, lung, breast, or colorectal cancers. The treatment uses a radioactive drug that seeks out cancer cells to deliver radiation directly, aiming to kill them while sparing …

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This Phase 3 trial tests whether a combination of three drugs—camrelizumab, apatinib, and eribulin—works better than standard chemotherapy for advanced triple-negative breast cancer. The study will enroll 246 women aged 18 to 70. Researchers will measure how long the cancer stays…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This study tests whether a drug called pegfilgrastim (Neulasta) can prevent a dangerous drop in white blood cells and fever (febrile neutropenia) in women with triple-negative breast cancer. The 40 participants receive the drug after each round of AC chemotherapy, which follows e…

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

This study tests whether adding a drug called tetrathiomolybdate (TM) to standard chemotherapy (capecitabine) can reduce the risk of cancer spreading in people with high-risk triple-negative breast cancer. The trial has two parts: first, a small safety phase, then a larger random…

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…

This study tests a new drug called JSKN016 against standard treatments for people with advanced triple-negative breast cancer that has not responded to at least two prior therapies. The goal is to see if JSKN016 can slow cancer growth or extend survival. About 364 adults aged 18 …

This Phase 2 trial tests two different drug combinations—JS207 plus 9MW2821 or JS207 plus albumin paclitaxel—as a first treatment for people with recurrent or metastatic triple-negative breast cancer. The study will enroll 80 participants to see if these combinations can shrink t…

This study looks at whether taking vitamin D supplements during standard chemotherapy can help more tumors disappear in people with triple-negative breast cancer who are low in vitamin D. About 50 participants will receive vitamin D plus chemotherapy, and researchers will compare…

This early-stage trial is testing a new drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer therapies. The main goals are to…

This study tests whether two drugs, pembrolizumab and lenvatinib, can shrink brain tumors in people with breast cancer, lung cancer, or other solid tumors that have spread to the brain. About 87 participants will receive the combination therapy. The goal is to see how well the tr…

This study tests whether giving treatments based on the genetic makeup of a person's triple-negative breast cancer can shrink tumors or slow the disease. It is for people whose cancer has not responded to standard therapies. About 120 women will receive a treatment chosen specifi…

This early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, an…

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple proteins on breast cancer cells. It is for people with advanced or metastatic breast cancer, including HER2-positive and triple-negative types, who have not responded to s…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This phase 2 trial tests whether injecting the experimental drug INT230-6 directly into the tumor before standard chemotherapy and immunotherapy can improve outcomes for people with early triple-negative breast cancer (TNBC). About 61 participants will be randomly assigned to rec…

This study tests a more personalized chemotherapy plan for women with early-stage triple-negative breast cancer. The treatment is adjusted based on immune system activity in the tumor and imaging results. The goal is to see if a lighter chemo can still be effective, reducing side…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This study tests whether adding the drug VEGFR BP102 to standard chemotherapy (nab-paclitaxel) helps people with a specific, hard-to-treat form of advanced triple-negative breast cancer (called BLIS subtype). About 134 participants who have not had prior treatment for metastatic …

This early-phase study tests a new drug, ASP1002, in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants receive the drug throug…

This early-phase trial is testing a new drug called bulumtatug furvedotin (BFv) in 52 people with triple-negative breast cancer that has come back or spread to other parts of the body. Participants must have already received certain types of chemotherapy and antibody-drug conjuga…

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin and paclitaxel) can improve outcomes for people with stage 1 triple-negative breast cancer. The study will enroll 28 participants at MD Anderson Canc…

This study tests whether giving a very focused, high-dose radiation treatment (SBRT) to all visible cancer spots can delay the cancer from getting worse in people with breast or lung cancer that has spread to 1-5 places. About 145 participants will either receive standard care al…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This study tests a new drug called MBRC-201 in people with advanced solid tumors (prostate, breast, colorectal, lung, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly …

This study tests a specific chemotherapy combination (epirubicin + cyclophosphamide followed by docetaxel + carboplatin) in 85 Nigerian women with triple-negative breast cancer. The main goal is to see how many women have no cancer left in their breast or lymph nodes after treatm…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 adul…

This study tests a new drug called LBL-024, either by itself or combined with chemotherapy (albumin-bound paclitaxel), in people whose triple negative breast cancer has come back or spread. The goal is to see if the drug can shrink tumors and control the disease. About 220 adults…

This study tests whether using a patient's genetic profile to customize radiation doses can better control triple negative breast cancer after lumpectomy. About 86 participants will receive genomically guided radiation therapy. The goal is to prevent cancer from returning in the …

This study tests whether giving immunotherapy every 6 weeks instead of every 3 weeks works as well for advanced triple-negative breast cancer. The goal is to keep the cancer under control while reducing side effects and improving quality of life. About 416 participants whose canc…

This early-phase study tests an experimental vaccine made from a patient's own immune cells, designed to target two cancer-related proteins (HER2 and HER3). The vaccine is injected directly into the tumor alongside standard chemotherapy before surgery. The goal is to find the saf…

This early-stage trial is testing a treatment called X-PACT for people with advanced head and neck cancer, breast cancer, soft tissue sarcoma, or melanoma that has not responded to standard treatments. X-PACT involves injecting a drug called methoxsalen directly into the tumor an…

This study tests a different dose and schedule of the drug sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has not responded to prior treatment. The trial has two phases: phase 1 checks safety and the best dose, and phase 2 measures how…

This phase II trial is testing a combination of two drugs—Sac-TMT (a targeted chemotherapy) and KL-A167 (an immunotherapy)—given before surgery to 40 people with triple-negative breast cancer. The goal is to see if the combo can eliminate or shrink tumors enough to improve long-t…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This phase 3 trial tests whether adding an anti-vascular drug to standard chemotherapy can help prevent cancer from returning in people with a specific, aggressive type of triple-negative breast cancer. About 764 women with stage II to III cancer will receive either the combinati…

This phase II trial tests whether adding an experimental drug called INBRX-106 to the immunotherapy pembrolizumab (Keytruda) can shrink tumors in people with stage II or III triple-negative breast cancer before they receive standard chemotherapy. The study will enroll 12 adults w…

This early-stage study tests a new drug called NM6603 in about 30 adults with advanced solid tumors (mainly colorectal or triple-negative breast cancer) who have run out of standard options. The main goal is to find the safest dose and check how the drug moves through the body. P…

This early-stage study tests an experimental oral drug called DPTX3186 in 40 adults with advanced solid tumors (like colorectal, gastric, lung, or triple-negative breast cancer) that are linked to a specific cell signal called Wnt. These participants have no other approved treatm…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This study tests a combination of three drugs (atezolizumab, vinorelbine, and cyclophosphamide) in people with advanced triple-negative breast cancer that has spread. Participants have already received immunotherapy before. The goal is to see if this new mix can shrink tumors or …

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an…

This study tests a new treatment called GO306, a modified virus designed to infect and destroy cancer cells. It is for adults with advanced solid tumors (like breast, colon, or kidney cancer) that have not responded to standard therapies. The main goal is to check the safety of t…

This early-phase trial is testing whether giving two drugs—lenvatinib and pembrolizumab—before surgery can boost the immune response in people with early-stage triple-negative breast cancer. Only 12 participants will receive the short treatment before their planned surgery. The m…

This phase 3 trial is testing whether adding the antibiotic moxifloxacin to standard chemotherapy (gemcitabine and carboplatin) helps people with metastatic triple-negative breast cancer live longer without their cancer growing. About 228 participants will receive either the anti…

This study tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (Camrelizumab) given before surgery can eliminate all cancer in patients with early triple-negative breast cancer. About 64 participants will receive this trea…

This study tests whether adding two drugs (sacituzumab govitecan and zimberelimab) to precise brain radiation can help people with metastatic triple negative breast cancer that has spread to the brain. The trial will enroll 31 adults and compare the combination against sacituzuma…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenousl…

This phase 2 trial is testing several drug combinations (including choline, sodium cromoglicate, efavirenz, and others) alongside immunotherapy to see if they can reverse resistance in triple-negative breast cancer that has progressed after prior immunotherapy. About 80 participa…

This phase 2 trial is for people with early-stage triple-negative breast cancer that has a high level of immune cells (TILs) in the tumor. It tests whether some patients can safely skip chemotherapy and just be monitored, while others receive a combination of the immunotherapy dr…

This study tests whether adding retinoic acid (a vitamin A derivative) to an immune checkpoint inhibitor can help shrink tumors or slow disease progression in people with HER2-negative breast cancer whose cancer stopped responding to prior immunotherapy. About 10 participants wil…

This early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much rad…

This phase 3 trial is testing whether a targeted drug called sacituzumab govitecan (Trodelvy), alone or combined with the immunotherapy pembrolizumab (Keytruda), can effectively treat low-risk triple-negative breast cancer before surgery. The study aims to see if these drugs can …

This study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…

This study tests whether a structured nutrition and exercise program can improve the chance of a complete response to pre-surgery chemo-immunotherapy in women with triple-negative breast cancer. About 160 women who are not currently exercising or eating many fruits and vegetables…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and …

This pilot study tests whether adjusting chemotherapy based on early PET scan results can improve outcomes for people with stage 2 or 3 triple negative breast cancer. Participants receive four cycles of chemotherapy plus the immunotherapy drug pembrolizumab. A PET scan after the …

This phase 2 trial is testing whether women with HER2-positive or triple-negative breast cancer who have a complete response to chemotherapy can safely skip surgery or radiation. The study will enroll 152 women and monitor them for cancer recurrence, distant spread, or death. The…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This phase 2 trial compares two chemotherapy combinations given before surgery for triple-negative breast cancer. About 520 women will receive either nab-paclitaxel plus carboplatin or nab-paclitaxel plus epirubicin. The goal is to see which combo better eliminates cancer cells i…

This Phase 2 trial is testing two different chemotherapy combinations in 414 women with advanced triple-negative breast cancer (TNBC), a fast-growing type that lacks common treatment targets. One group gets nab-paclitaxel plus carboplatin, the other gets nab-paclitaxel plus capec…

This study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to …

This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

This early-phase study is testing whether a special PET scan tracer, originally used for prostate cancer, can detect metastatic triple negative breast cancer. Thirty women with advanced disease will receive both standard FDG PET and the new PSMA PET scan. The goal is to see if PS…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This study compares a special contrast-enhanced mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether breast cancer has been eliminated by chemotherapy. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms durin…

This study is testing whether a special whole-body MRI scan can find breast cancer that has come back or spread to other parts of the body earlier than standard methods. Researchers will follow 145 women with aggressive breast cancer types (HER2+ or triple-negative) for five year…

This study is testing whether a new type of PET scan (68Ga-FAPI-46) can predict if triple-negative breast cancer will completely respond to chemotherapy plus immunotherapy before treatment begins. About 60 women with early-stage, high-risk breast cancer will get the scan before s…

This study is looking at whether a brain MRI can spot cancer that has spread to the brain in people with certain types of breast cancer (triple negative or HER2-positive, stage IIb or III) who have no symptoms. About 100 participants will get a contrast-enhanced brain MRI, give a…

This study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This pilot study tests whether a special type of PET/MRI scan can monitor how triple-negative breast cancer responds to immunotherapy. Twenty patients will get three scans over their first two treatment cycles. The results won't change their care but could help design larger stud…

This study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …

This study looks at how a single session of aerobic exercise—either moderate or high intensity—affects breast cancer cells in the lab. Researchers will take blood from breast cancer survivors before and after exercise, then see if that blood slows the growth of breast cancer cell…

This study looks at how well standard chemotherapy works in people with triple-negative breast cancer, an aggressive type that lacks targeted treatments. Researchers will also measure tiny molecules called microRNAs and tumor DNA in the blood to see if changes can signal when the…

This study takes tumor samples from people with triple-negative breast cancer, colorectal cancer, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse tumors to see which ones might work best for each person. The goal is to provide person…

This study looks at whether a blood test can find tiny bits of tumor DNA (ctDNA) in people with early-stage triple-negative breast cancer. Researchers will collect blood samples before and during treatment to see if the test can help predict if the cancer might come back. About 7…

This study is for 500 adults with non-metastatic breast cancer who are about to start treatment like chemotherapy or targeted therapy before surgery. Researchers will collect tumor tissue, blood, and sometimes stool samples and MRI scans during treatment. The goal is to learn why…

This study tests a simple blood test (liquid biopsy) to see if it can tell which triple-negative breast cancer patients will benefit from the drug capecitabine after standard chemotherapy. About 40 adults with leftover cancer after chemo will give blood samples before and during …

This study takes tumor samples from women with aggressive breast cancers (triple-negative or luminal B) and grows them in mice to create patient-derived xenografts (PDX). The goal is to see how well these mouse models mimic the original tumors and to learn about tumor evolution a…

This study takes small tumor samples from people with triple-negative breast cancer and grows them in the lab as 3D mini-tumors called organoids. Researchers will test different cancer drugs on these organoids to see which ones work best and look for clues that could predict a pa…

This study is for women with breast cancer who are receiving a treatment that greatly lowers estrogen levels. Researchers want to see if this treatment changes how the heart works. They will use heart scans to measure blood flow in 90 women over two years. The goal is to learn mo…

This study looks at whether it is possible to take multiple tissue samples (biopsies) from different tumor sites in people with metastatic breast cancer at different times during treatment. The goal is to learn how cancers change and become resistant to therapy. About 200 adults …

This study looks at bacteria living in breast tumors of people with triple negative breast cancer. Researchers want to see if these bacteria can help predict who will respond well to chemotherapy and immunotherapy before surgery. The study will collect tumor samples before and af…

This study is testing a new approach called Functional Precision Oncology for people with triple-negative or HR-low/HER2- breast cancer at high risk of early recurrence. Researchers will create personalized tumor models (in mice and lab dishes) from each patient's cancer to find …

This study is for people with high-risk early breast cancer, including inflammatory breast cancer. Researchers want to see if clusters of tumor cells found in the blood can help predict how well treatment works and the chances of survival. About 130 participants will give blood s…

This study is collecting tumor samples from 1,050 people with early or metastatic breast cancer to analyze fat storage and organelle properties in cancer cells. Researchers aim to create a detailed atlas of these features across different breast cancer subtypes. The goal is to be…

This study collects tumor and blood samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). Researchers will analyze the samples to find links between genetic changes, the immune system, and how the cancer behaves. Parti…

This study looks at whether regular blood tests (ctDNA monitoring) combined with a special type of PET scan can detect the return of triple negative breast cancer earlier than standard methods. About 450 women who finished treatment for early-stage triple negative breast cancer w…

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study looks at whether combining four types of scans (ultrasound, mammography, MRI, and PET-CT) can accurately predict if triple-negative breast cancer has been completely eliminated by chemotherapy and immunotherapy. Researchers will also check blood markers to identify whi…

This study is looking at proteins called selenoproteins in people with triple-negative breast cancer (TNBC), a hard-to-treat type. Researchers will measure these proteins in tumor samples and blood from 300 patients and 100 healthy women. The goal is to see if selenoproteins can …

This study looks at whether a person's mental state—like anxiety or depression—can influence how well immunotherapy works for triple-negative breast cancer. About 120 women will receive standard treatment, complete psychological surveys, and give blood and saliva samples. Researc…

This study looks at whether the phase of a woman's menstrual cycle when she starts chemotherapy affects how well the treatment works for breast cancer. Researchers will collect a blood sample from 100 premenopausal women with triple-negative breast cancer on the day they begin ne…

This study aims to develop a blood test that uses artificial intelligence to analyze tumor material in the blood of people with triple negative breast cancer. The goal is to better predict which patients need more chemotherapy after surgery and which can safely avoid it. Research…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help predict how well breast cancer responds to chemotherapy given before surgery. Researchers will take blood samples from 125 women with stage II or III breast cancer before, during, and after treat…